## Clinical Scenario Analysis This patient has **smear-negative pulmonary TB** confirmed by GeneXpert MTB/RIF (which detects both viable and dead bacilli and is more sensitive than smear microscopy). She is responding well to standard therapy with good adherence and no adverse effects. ## Key Point: **Smear-negative TB patients receive the SAME 6-month standard regimen (2 months HRZE + 4 months HR) as smear-positive patients.** Smear negativity does not indicate treatment failure or warrant regimen change if the patient is clinically improving and adherent. ## High-Yield: Treatment response assessment in TB: | Time Point | Smear-Positive TB | Smear-Negative TB | Action | |------------|------------------|-------------------|--------| | 2 months (end of IP) | Should convert to smear-negative | Remains negative (expected) | **Continue standard therapy** | | Clinically improving | Yes | Yes | Continue current regimen | | Adherent, no AE | Yes | Yes | No change needed | | CXR improvement | Expected by 3–4 months | Expected by 3–4 months | Continue therapy | ## Clinical Pearl: **Smear conversion in smear-positive patients and clinical improvement in smear-negative patients are markers of good treatment response.** Continuing the standard 6-month course ensures: 1. Sterilization of lesions 2. Prevention of relapse (occurs in ~5% if therapy shortened) 3. Prevention of drug resistance ## Mnemonic: HRZE Duration **HRZE = 2 months (Intensive Phase)** **HR = 4 months (Continuation Phase)** **Total = 6 months for drug-susceptible TB** This applies to **both smear-positive AND smear-negative TB** with good clinical response.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.